STOCKHOLM
Japanese drugmaker Eisai's experimental blood clot preventer E5555 may have the potential to reduce heart attacks, strokes and cardiovascular deaths without increased serious
bleeding risks, Japanese researchers said.
Two Phase II clinical trials presented at the European Society of Cardiology congress today showed that while there was a trend towards increased bleeding as the dose of E5555 increased, serious bleeding risks were not significantly higher.
No comments:
Post a Comment